AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Collaboration Aims To Elicit Broader, Stronger Immune Response Against HIV.(Brief Article)
2001 APR 11 - (NewsRx.com & NewsRx.net) --
Maxygen Inc. (MAXY), the International AIDS Vaccine Initiative (IAVI), and DBLV LLC, an entity established and funded by the Rockefeller Foundation, announced the formation of a three-year collaboration to develop novel HIV vaccines using Maxygen's proprietary MolecularBreeding(TM) directed molecular evolution technologies.
The parties believe these technologies can potentially overcome key obstacles that have hindered the development of AIDS vaccines, such as insufficient immune response and the inability to protect against infection by different strains of HIV.
Under the agreement, DBLV will provide full research and development funding to Maxygen for at least three years to expand its ongoing program in HIV vaccine development. Maxygen will retain all rights to commercialize the HIV vaccine candidates in all developed countries of the world, as well as in certain markets in the developing world. In recognition of the great need for a vaccine against AIDS in the poorest countries of the world where infection rates are soaring, Maxygen has granted IAVI a royalty-free license to develop and distribute HIV vaccines to those who cannot afford them in developing countries.
The collaboration has the potential in the future to expand its current focus on HIV vaccine discovery to include development of HIV vaccines leveraging IAVI's know-how and access to an extensive clinical infrastructure.
...
- HIV vaccine antibodies bind more poorly than natural infection antibodies.
- Newspaper article from: Vaccine Weekly March 24, 2004 700+ words
...major subject areas of AIDS and HIV Vaccine, Vaccine Development, Immunology...Virology. This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx...
- Assays with extended incubation phases needed to monitor HIV vaccine trials.
- Newspaper article from: Vaccine Weekly April 21, 2004 700+ words
...to monitor current HIV vaccine efficacy trials...subject areas of AIDS and HIV Vaccine, Vaccine Efficacy...article was prepared by Vaccine Weekly editors from staff...Copyright 2004, Vaccine Weekly via NewsRx.com...
- Components of HIV vaccine are recognized by T-helper cells.
- Newspaper article from: Vaccine Weekly May 19, 2004 700+ words
...of a multi-envelope HIV vaccine are recognized by type...of a multi-envelope HIV vaccine are recognized by type...subject areas of AIDS and HIV Vaccine, AIDS and HIV Therapy...article was prepared by Vaccine Weekly editors from staff and...
- CTL ontogeny and viral escape have implications for HIV vaccine design.
- Newspaper article from: Vaccine Weekly May 19, 2004 700+ words
...have implications for HIV vaccine design. According...subject areas of AIDS and HIV Vaccine, AIDS and HIV Therapy...article was prepared by Vaccine Weekly editors from staff...Copyright 2004, Vaccine Weekly via NewsRx.com...
- Scientific challenges impeding HIV vaccine development reviewed.
- Newspaper article from: Vaccine Weekly January 28, 2004 700+ words
...scientific challenges impeding HIV vaccine development were reviewed...subject areas of AIDS and HIV Vaccine, AIDS and HIV Therapy...This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com &...
- FDA accepts IND for unique HIV vaccine.
- Newspaper article from: Vaccine Weekly April 21, 2004 700+ words
...by UMMS and ABL. The HIV Vaccine project has been funded...date, under a 5-year HIV Vaccine Design & Development...responsibility for the HIV vaccine FDA registration following...article was prepared by Vaccine Weekly editors from staff and...
- IND application filed for unique HIV vaccine.
- Newspaper article from: Vaccine Weekly February 25, 2004 700+ words
...the combination of the HIV vaccine technology with DNA...ABL for the current HIV vaccine that is being developed...In addition to the HIV vaccine technology, CytRx also...article was prepared by Vaccine Weekly editors from staff and...
- Investigational new drug application to be filed for HIV vaccine.
- Newspaper article from: Vaccine Weekly January 21, 2004 700+ words
...the combination of the HIV vaccine technology owned by...ABL for the current HIV vaccine that is being developed...In addition to the HIV vaccine technology, CytRx also...article was prepared by Vaccine Weekly editors from staff and...
Source: HighBeam Research, Collaboration Aims To Elicit Broader, Stronger Immune Response...